APP and Alzheimer disease: As a key enzyme in the amyloidogenic pathway of APP processing, BACE1 activity and expression are significantly upregulated in AD brains compared to non-demented controls, making BACE1 a focal point in AD treatment strategies (Yang et al. 2003).